Compare GraniteShares 2x Long NVDA Daily ETF (NVDL) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GraniteShares 2x Long NVDA Daily ETF vs Viatris Inc — how do they compare? GraniteShares 2x Long NVDA Daily ETF trades at $36.86 (market cap $3.56B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 5.6× GraniteShares 2x Long NVDA Daily ETF's market cap, and Viatris Inc pays a 2.75% dividend while GraniteShares 2x Long NVDA Daily ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GraniteShares 2x Long NVDA Daily ETF for 15 Days and Viatris Inc for 57 Days on average.
| NVDL | VTRS | |
|---|---|---|
Market Cap | $3.56B | $20.03B |
Volume | 9,740,643 | 14,109,977 |
Sector | Leveraged / Inverse | Health |
52-Week High | $43.02 | $18.27 |
52-Week Low | $21.76 | $9.74 |
Typical Hold Time | 15 Days | 57 Days |
Enterprise Value | — | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVDL, the GraniteShares 2x Long NVDA Daily ETF, trades at $37.28, down 5.79% in the last session. Technical indicators show a bullish overall signal with moving averages supporting upside momentum while oscillators remain neutral. The ETF tracks Nvidia's performance with 2x daily leverage, benefiting from Nvidia's strong AI leadership and consistent earnings beats. Recent news highlights Nvidia's continued dominance in AI chips and the ETF's leveraged exposure to this growth story.
The outlook remains positive given Nvidia's AI market leadership and technical breakout potential, though leveraged ETF structure introduces volatility decay risks. Key support sits at $36 with resistance at $39-41. Investors should monitor Nvidia's earnings performance and broader AI sector trends for directional cues.
Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical outlook supported by moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, though it faces profitability challenges with negative net margins. Recent positive developments include FDA approval for WAKIX in Japan and consistent dividend payments, while analyst consensus leans toward a buy rating with a $22.17 price target representing 27% upside potential.
The stock presents a value opportunity with reasonable P/S and P/B ratios, but investors must weigh strong cash generation against persistent profitability issues. Key catalysts include continued earnings beats and pipeline progress, while risks involve margin pressure and high debt levels. The current valuation disconnect between technical strength and fundamental challenges creates a balanced risk-reward profile for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GraniteShares 2x Long NVDA Daily ETF
NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
